Detalhe da pesquisa
1.
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Int J Gynecol Cancer
; 32(1): 93-100, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34799418